Raptor Pharmaceutical Corp. Director Sells $241,570 in Stock (RPTP)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Director Erich Sager unloaded 17,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $14.21, for a total transaction of $241,570.00. Following the completion of the transaction, the director now directly owns 130,727 shares in the company. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
RPTP has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $12.00 to $14.00 in a research note to investors on Friday, August 9th. Separately, analysts at JMP Securities raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $13.00 to $15.00 in a research note to investors on Friday, August 9th. Finally, analysts at Canaccord Genuity raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $14.00 to $16.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock.
One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $12.17.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 0.35% on Wednesday, hitting $14.35. 600,354 shares of the company’s stock traded hands. Raptor Pharmaceutical Corp. has a 1-year low of $4.35 and a 1-year high of $14.90. The stock’s 50-day moving average is $12.5 and its 200-day moving average is $8.5. The company’s market cap is $856.1 million.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.30) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.30). Analysts expect that Raptor Pharmaceutical Corp. will post $-1.24 EPS for the current fiscal year.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.